DDInter1943 DDInter298
In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Vitamin E {u} (Compound) binds {v} (Gene) SOD1
SOD1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Vitamin E {u} (Compound) binds {v} (Gene) SOD1
SOD1 {u} (Gene) is associated with {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Vitamin E {u} (Compound) binds {v} (Gene) SOD1
SOD1 {u} (Gene) regulates {v} (Gene) MT2A
MT2A {u} (Gene) is bound by {v} (Compound) Carboplatin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Vitamin E {u} (Compound) downregulates {v} (Gene) SMC1A
SMC1A {u} (Gene) is associated with {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Vitamin E {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is associated with {v} (Disease) brain cancer
brain cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Vitamin E (Compound) binds SOD1 (Gene) and SOD1 (Gene) is bound by Carboplatin (Compound)
Vitamin E (Compound) binds SOD1 (Gene) and SOD1 (Gene) is associated with ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Carboplatin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Vitamin E (Compound) binds SOD1 (Gene) and SOD1 (Gene) regulates MT2A (Gene) and MT2A (Gene) is bound by Carboplatin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Vitamin E (Compound) downregulates SMC1A (Gene) and SMC1A (Gene) is associated with urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Carboplatin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)
Vitamin E (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is associated with brain cancer (Disease) and brain cancer (Disease) is treated by Carboplatin (Compound)